135748-35-5|4-Chloro-2,5-difluorobenzonitrile| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 135748-35-5 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 135748-35-5 ]

CAS No. :	135748-35-5
Formula :	C₇H₂ClF₂N
M.W :	173.55
SMILES Code :	FC1=CC(C#N)=C(F)C=C1Cl
MDL No. :	MFCD06659464
InChI Key :	OMVDTUXOHXQKML-UHFFFAOYSA-N
Pubchem ID :	11275302

Safety of [ 135748-35-5 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P280-P305+P351+P338

Computational Chemistry of [ 135748-35-5 ] Show Less

Physicochemical Properties

Num. heavy atoms	11
Num. arom. heavy atoms	6
Fraction Csp3	0.0
Num. rotatable bonds	0
Num. H-bond acceptors	3.0
Num. H-bond donors	0.0
Molar Refractivity	36.08
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	23.79 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.77
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.47
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	3.33
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	2.9
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	3.29
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.75

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.88
Solubility	0.231 mg/ml ; 0.00133 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.61
Solubility	0.422 mg/ml ; 0.00243 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-3.65
Solubility	0.0385 mg/ml ; 0.000222 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.6 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	2.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.95

Application In Synthesis of [ 135748-35-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 135748-35-5 ]

[ 135748-35-5 ] Synthesis Path-Downstream 1~31

1
[ 135748-35-5 ]
[ 100306-33-0 ]
[ 765-30-0 ]
4-Chloro-2-[(1R)-3-(cyclopropylamino)-1-phenylpropyl]oxy}-5-fluorobenzonitrile oxalate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium iodide; oxalic acid; triethylamine; In tetrahydrofuran; N-methyl-acetamide; methanol; water; mineral oil;	EXAMPLE 25 4-Chloro-2-[(1R)-3-(cyclopropylamino)-1-phenylpropyl]oxy}-5-fluorobenzonitrile oxalate (R)-alpha-(2-Chloroethyl)benzenemethanol (341 mg, 2 mmol) was dissolved in tetrahydrofuran (10 ml) and treated with sodium hydride as a 60% suspension in mineral oil (480 mg, 3 mmol) followed after 10 minutes by <strong>[135748-35-5]4-chloro-2,5-difluorobenzonitrile</strong> (347 mg, 2 mmol). The mixture was stirred at room temperature for 18 h before being treated with methanol (1 ml) and then water (10 ml). The tetrahydrofuran was then removed via heating the vessel to 80 C. and applying a nitrogen stream. Once the tetrahydrofuran was evaporated the residue was extracted into dichloromethane, dried over magnesium sulphate and concentrated in vacuo. The resultant material was re-dissolved into dimethylformamide (8 ml) and treated with sodium iodide (305 mg, 2.03 mmol), triethylamine (565 mul, 4.06 mmol) and cyclopropylamine (114 mg, 2 mmol) before being heated to 60 C. for 5 days. The mixture was filtered and purified via RPHPLC on the crude reaction material. The purified compound was then treated with 50% saturated oxalic acid in ether to produce 74 mg of a white powder that was collected via filtration. MS APCI+ve m/z 345/347 [(M+H)+]. 1H NMR 400 MHz (d6-DMSO) 7.97-7.87 (m, 1H), 7.53-7.25 (m, 6H), 5.69 (m, 1H), 3.28-3.07 (m, 2H), 2.80-2.68 (m, 1H), 2.45-2.29 (m, 1H), 2.29-2.12 (m, 1H), 0.85-0.74 (m, 4H).

References: [1]Patent: US2003/158185,2003,A1 .

2
[ 135748-35-5 ]
[ 357404-66-1 ]
[ 765-30-0 ]
4-Chloro-2-[(1R)-3-(cyclopropylamino)-1-(3-furanyl)propyl]oxy}-5-fluorobenzonitrile oxalate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
1.6%	With oxalic acid;	EXAMPLE 26 4-Chloro-2-[(1R)-3-(cyclopropylamino)-1-(3-furanyl)propyl]oxy}-5-fluorobenzonitrile oxalate Prepared by the method of Example 25 using (R)-alpha-(2-chloroethyl)-3-furanmethanol (321 mg, 2 mmols) and <strong>[135748-35-5]4-chloro-2,5-difluorobenzonitrile</strong> (347 mg, 2 mmols) initially before converting into the title compound via in situ conversion to the iodo compound and treatment with cyclopropylamine. The free base was treated with a 50% saturated solution of oxalic acid in ether. The resultant white solid was collected via filtration to yield the title compound (14 mg, 1.6%). MS APCI+ve m/z 335/337 [(M+H)+]. 1H NMR 400 MHz (d6-DMSO) 8.01 (d, 1H), 7.70 (s, 1H), 7.70 (s, 1H), 7.59 (d, 1H), 6.53 (s, 1H), 5.72 (t, 1H), 3.15-2.99 (m, 2H), 2.97-2.87 (m, 1H), 2.40-2.26 (m, 1H), 2.24-2.09 (m, 1H), 0.78-0.66 (m, 4H).

References: [1]Patent: US2003/158185,2003,A1 .

3
[ 135748-35-5 ]
[ 357405-59-5 ]
[ 765-30-0 ]
4-Chloro-2-[(1R)-3-(cyclopropylamino)-1-(thien-3-yl)propyl]oxy}-5-fluorobenzonitrile oxalate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
3%	With oxalic acid;	EXAMPLE 27 4-Chloro-2-[(1R)-3-(cyclopropylamino)-1-(3-thienyl)propyl]oxy}-5-fluorobenzonitrile oxalate Prepared by the method of Example 25 using (R)-alpha-(2-chloroethyl)-3-thiophenemethanol (Example 74(d)) and <strong>[135748-35-5]4-chloro-2,5-difluorobenzonitrile</strong> initially before converting into the title compound via i7l situ conversion to the iodo compound and treatment with cyclopropylamine The free base was treated with a 50% saturated solution of oxalic acid in ether. The resultant white solid was collected via filtration to yield the title compound (24 mg, 3%). MS APCI+ve m/z 351 [(M+H)+]. 1H NMR 400 MHz (d6-DMSO) 8.02 (d, 1H), 7.60 (s, 2H), 7.50 (d, 1H), 7.14 (d, 1H), 5.83 (t, 1H), 3.14-2.99 (m, 2H), 2.76-2.62 (m, 1H), 2.42-2.29 (m, 2H), 2.27-2.13 (m,2H), 0.84-0.63 (m, 4H).

References: [1]Patent: US2003/158185,2003,A1 .

4
[ 135748-35-5 ]
[ 357404-66-1 ]
[ 109-85-3 ]
4-Chloro-5-fluoro-2-({(1R)-1-(3-furanyl)-3-[(2-methoxyethyl)amino]propyl}oxy)benzonitrile oxalate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium iodide; oxalic acid; triethylamine; In tetrahydrofuran; water; N,N-dimethyl-formamide; mineral oil;	b 4-Chloro-5-fluoro-2-({(1R)-1-(3-furanyl)-3-[(2-methoxyethyl)amino]propyl}oxy)benzonitrile oxalate (R)-alpha-(2-Chloroethyl)-3-furanmethanol (100 mg, 0.62 mmol) was dissolved in tetrahydrofuran (5 ml) at room temperature. To this solution was added sodium hydride as a 60% suspension in mineral oil (3 7 mg, 0.93 mmol) and the mixture was stirred for 10 minutes before solid <strong>[135748-35-5]4-chloro-2,5-difluorobenzonitrile</strong> (107.6 mg, 0.62 mmol) was added in one portion. The resultant mixture was stirred for 1 h before water (2 ml) was added and the mixture concentrated in vacuo. The residues were partitioned between dichloromethane and water. The organics were collected, dried over magnesium sulphate, filtered and concentrated to dryness in vacuo. The resultant residue was dissolved in N,N-dimethylformamide (2 ml) and treated with sodium iodide (93 mg, 0.62 mmol), triethylamine (172 mul, 1.24 mmol) and 2-methoxyethanamine (107 mul, 1.24 mmol) before being heated to 60 C. for 72 h. After being allowed to cool the mixture was filtered and purified via reverse phase HPLC to give the title compound as a free base which was treated with a 50% saturated solution of oxalic acid in ether. The resultant white solid was collected via filtration to yield the title compound (61 mg, 28%). MS APCI+ve m/z 353/355 [(M+H)+]. 1H NMR 300 MHz (d6-DMSO) 8.02 (1H, d), 7.82 (1H, s), 7.70 (1H, s), 7.59 (1H, s), 5.72 (2H, t), 3.57 (2H, m), 3.31 (3H, s), 3.16 (2H, m), 3.09-2.98 (2H, b), 2.37 (1H, bm), 2.27 (1H br m).

References: [1]Patent: US2003/158185,2003,A1 .

5
[ 135748-35-5 ]
[ 357405-60-8 ]

Yield	Reaction Conditions	Operation in experiment
		e 4-Chloro-2-[[(1R)-3-chloro-1-(3-thienyl)-propyl]oxy]-5-fluoro-benzonitrile Using the product of step (d) (322 mg, 1.84 mmol), <strong>[135748-35-5]4-chloro-2,5-difluorobenzonitrile</strong> (320 mg, 1.84 mmol) and the procedure described in Example 72(c), the title compound was prepared (540 mg, 89%). 1H NMR 300 MHz (CDCl3) 7.35-7.40 (1H, m), 7.29-7.34 (1H, m), 7.25-7.28 (1H, m), 7.11 (1H, dt), 6.95-6.99 (1H, m), 5.54-5.63 (1H, m), 3.78-3.90 (1H, m), 3.55-3.66 (1H, m), 2.53-2.65 (1H, m), 2.21-2.35 (1H, m).

References: [1]Patent: US2003/158185,2003,A1 .

6
[ 135748-35-5 ]
[ 357406-00-9 ]

Yield	Reaction Conditions	Operation in experiment
		b 2-[[(1R)-3-Azido-1-(3-isoxazolyl)propyl]oxy]-4-chloro-5-fluorobenzonitrile The product from step (a) (0.1 g) and 2,5-difluoro-4-chloro-benzonitrile (0.18 g) and sodium hydride (60% dispersion in oil, 0.035 g) were subjected to the procedure described in Example 90(a) to afford the product as a gum (0.15 g). MS APCI+ve m/z 294 [(M-28)+].

References: [1]Patent: US2003/158185,2003,A1 .

7
[ 135748-35-5 ]
[ 32541-33-6 ]
[ 109-85-3 ]
4-Chloro-2-[1-ethyl-3-[(2-methoxyethyl)amino]propoxy]-5-fluorobenzonitrile Oxalate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium iodide; oxalic acid; triethylamine; In tetrahydrofuran; methanol; water; N,N-dimethyl-formamide; mineral oil;	EXAMPLE 25 4-Chloro-2-[1-ethyl-3-[(2-methoxyethyl)amino]propoxy]-5-fluorobenzonitrile Oxalate 1-Chloro-3-pentanol (1 g, 8.15 mmol) was dissolved in tetrahydrofuran (20 ml) and treated with sodium hydride as a 60% suspension in mineral oil (480 mg, 12.2 mmol) followed after 10 minutes by <strong>[135748-35-5]4-chloro-2,5-difluorobenzonitrile</strong> (1.41 g, 8.15 mmol). The mixture was stirred at room temperature for 18 h before being treated with methanol (1 ml) and then water (10 ml). The tetrahydrofuran was then removed via heating the vessel to 80 C. and applying a nitrogen stream. Once the tetrahydrofuran was evaporated off, the residue was extracted into dichloromethane, dried over magnesium sulphate and concentrated in vacuo. The resultant material was re-dissolved into N,N-dimethylformamide (8 ml) and treated with sodium iodide (305 mg, 2.03 mmol), triethylamine (565 mul, 4.06 mmol) and 2-methoxyethanamine (352 mul, 4.06 mmol) before being heated to 60 C. for 5 days. The mixture was filtered and purified via RP-HPLC on the crude reaction material. The purified compound was then treated with 50% saturated oxalic acid in ether to produce a white powder which was collected via filtration. (378 mg, 15%). MS APCI+ve m/z 315 ([M+H]+). 1H NMR 300 MHz (d6-DMSO) 8.03 (1H, d), 7.65 (1H, d), 4.66 (1H, m), 3.56 (2H, m), 3.30 (3H, s), 3.14-3.06 (2H, m), 3.06-2.97 (2H, m), 2.03 (2H, m), 1.65 (2H, m), 0.92 (3H, t).

References: [1]Patent: US2003/65174,2003,A1 .

8
[ 170564-98-4 ]
[ 135748-35-5 ]
[ 357434-38-9 ]

Yield	Reaction Conditions	Operation in experiment
15%	In ethyl acetate; N-ethyl-N,N-diisopropylamine;	a 4-Chloro-5-Fluoro-2-[[(1R)-3-Hydroxy-1-Phenylpropyl]Amino]Benzonitrile <strong>[135748-35-5]4-Chloro-2,5-difluorobenzonitrile</strong> (1.0 g, 5.76 mmol) and (gamma1R)-gamma-aminobenzenepropanol (870 mg, 5.76 mmol) were heated in N,N-diisopropylethylamine (740 mg, 5.76 mmol) at 140 C. for 30 h. The reaction mixture was partitioned between ethyl acetate and water and the organic layer separated. The aqueous layer was further extracted with ethyl acetate, and the extracts combined and dried over anhydrous sodium sulphate. The solvent was evaporated and the residue purified by flash chromatography using 10% ethyl acetate/isohexane as eluent to give the title product (260 mg, 15%). MS APCI+vem/z305 ([M+H]+). 1H NMR 300 MHz (CDCl3) 7.33 (5H, m), 7.15 (1H, d), 6.43 (1H, d), 5.98 (1H, d), 4.61 (1H, d), 3.79 (2H, m), 2.11 (2H, m).

References: [1]Patent: US2003/73685,2003,A1 .

9
[ 135748-35-5 ]
[ 357416-59-2 ]
[3-(5-Chloro-2-cyano-4-fluorophenoxy)hexyl]methylcarbamic Acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In N,N-dimethyl-formamide;	a [3-(5-Chloro-2-cyano-4-fluorophenoxy)hexyl]methylcarbamic Acid, 1,1-dimethylethyl Ester The subtitle compound was prepared according to the method of Example 3 step (b) using (3-hydroxyhexyl)methylcarbamic acid, 1,1-dimethylethyl ester and <strong>[135748-35-5]4-chloro-2,5-difluorobenzonitrile</strong> in N,N-dimethylformamide. 1H NMR 300 MHz (CDCl3) 7.33 (1H, d), 6.99 (1H, bs), 4.33 (1H, m), 3.34 (2H, m), 2.85 (3H, s), 1.95 (2H, m), 1.70 (2H, m), 1.41 (11H, m), 0.95 (3H, t).

References: [1]Patent: US2003/65174,2003,A1 .

10
[ 135748-35-5 ]
[ 357416-53-6 ]
[3-(5-Chloro-2-cyano-4-fluorophenoxy)pentyl]methylcarbamic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In N,N-dimethyl-formamide;	a [3-(5-Chloro-2-cyano-4-fluorophenoxy)pentyl]methylcarbamic acid, 1,1-dimethylethyl Ester The subtitle compound was prepared according to the method of Example 3 step (b) using (3-hydroxypentyl)methylcarbamic acid, 1,1-dimethylethyl ester and <strong>[135748-35-5]4-chloro-2,5-difluorobenzonitrile</strong> in N,N-dimethylformamide. 1H NMR 300 MHz (CDCl3) 7.33 (1H, d), 6.99 (1H, s), 4.26 (1H, m), 3.34 (2H, m), 2.85 (3H, s), 1.96 (2H, m), 1.74 (2H, m), 1.41 (9H, s), 0.99 (3H, t).

References: [1]Patent: US2003/65174,2003,A1 .

11
[ 135748-35-5 ]
[ 357417-80-2 ]
[3-(5-Chloro-2-cyano-4-fluorophenoxy)-4,4,4-trifluorobutyl]methylcarbamic acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In N,N-dimethyl-formamide;	a [3-(5-Chloro-2-cyano-4-fluorophenoxy)-4,4,4-trifluorobutyl]methylcarbamic acid, 1,1-dimethylethyl Ester The subtitle compound was prepared according to the method of Example 3 step (b) using methyl-(4,4,4-trifluoro-3-hydroxybutyl)carbamic acid, 1,1-dimethylethyl ester and <strong>[135748-35-5]4-chloro-2,5-difluorobenzonitrile</strong> in N,N-dimethylformamide. 1H NMR 300 MHz (CDCl3) 7.37 (1H, d), 7.30 (1H, bm), 4.62 (1H, m), 3.80 (1H, bm), 3.20 (1H, bm), 2.86 (3H, s), 2.16 (2H, m), 1.40 (9H, s).

References: [1]Patent: US2003/65174,2003,A1 .

12
[ 135748-35-5 ]
[ 357416-77-4 ]
[3-(5-Chloro-2-cyano-4-fluorophenoxy)-4-pentenyl]methylcarbamic Acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In N,N-dimethyl-formamide;	b [3-(5-Chloro-2-cyano-4-fluorophenoxy)-4-pentenyl]methylcarbamic Acid, 1,1-dimethylethyl Ester The subtitle compound was prepared according to the method of Example 3 step (b) using (3-hydroxy-4-pentenyl)methylcarbamic acid, 1,1-dimethylethyl ester and <strong>[135748-35-5]4-chloro-2,5-difluorobenzonitrile</strong> in N,N-dimethylformamide. 1H NMR 300 MHz (CDCl3) 7.33 (1H, d), 7.00 (1H, d), 5.85 (1H, m), 5.30 (2H, m), 4.65 (1H, m), 3.35-3.51 (2H, m), 2.87 (3H, s), 1.97-2.10 (2H, m), 1.41 (9H, s).

References: [1]Patent: US2003/65174,2003,A1 .

13
[ 135748-35-5 ]
[ 357416-79-6 ]
[3-(5-Chloro-2-cyano-4-fluorophenoxy)-3-cyclopentylpropyl]methylcarbamic Acid [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In N,N-dimethyl-formamide;	b [3-(5-Chloro-2-cyano-4-fluorophenoxy)-3-cyclopentylpropyl]methylcarbamic Acid, 1,1-dimethylethyl Ester The subtitle compound was prepared according to the method of Example 3 step (b) using (3-cyclopentyl-3-hydroxypropyl)methylcarbamic acid, 1,1-dimethylethyl ester and <strong>[135748-35-5]4-chloro-2,5-difluorobenzonitrile</strong> in N,N-dimethylformamide. 1H NMR 300 MHz (CDCl3) 7.32 (1H, d), 7.04 (1H, bm), 4.28 (1H, m), 3.35 (2H, bm), 2.83 (3H, s), 2.28 (1H, m), 1.95 (2H, q), 1.50-1.80 (6H, m), 1.42 (9H, s), 1.26-1.45 (2H, m).

References: [1]Patent: US2003/65174,2003,A1 .

14
[ 135748-35-5 ]
[ 764648-44-4 ]

Yield	Reaction Conditions	Operation in experiment
35%		General procedure: Hydrogen chloride gas was passed through a solution of 4-chlorobenzonitrile (9b, 25.0 g) in chloroform (350 mL) and ethanol (100 mL) at -78 C for 0.5 h. Then the solution was warmed up to room temperature, and stirred at room temperature overnight. The solution was evaporated in vacuo, and the resulting residue was dissolved with ethanol (500 mL). To the solution was added ammonium carbonate (90.0 g), and the reaction mixture was stirred at room temperature for 3 days. To the mixture was added water (300 mL), and ethanol was removed by concentration in vacuo. The resulting solid was collected by filtration, washed with water and dried in vacuo to give 12b (25.4 g, 71%) as a white solid.
		Reference Example 1 A chloroform-EtOH solution of <strong>[135748-35-5]4-chloro-2,5-difluorobenzonitrile</strong> was saturated with hydrogen chloride by bubbling, stirred at ambient temperature for 16 hours, and then concentrated to yield an imidate, which was stirred together with ammonium carbonate in EtOH at ambient temperature for 3 days to yield 4-chloro-2,5-difluorobenzenecarboxamidine.

References: [1]Bioorganic and Medicinal Chemistry,2012,vol. 20,p. 5235 - 5246.
[2]Patent: EP1803710,2007,A1 .Location in patent: Page/Page column 11.

15
[ 135748-35-5 ]
[ 168465-69-8 ]
[ 357404-74-1 ]

Yield	Reaction Conditions	Operation in experiment
80%	With sodium hydride; In N,N-dimethyl-formamide; mineral oil; at 60℃; for 2h;Inert atmosphere;	A mixture of the (R)-alpha-(2-azidoethyl) benzenemethanol (8 g, 0.045 mol) and <strong>[135748-35-5]4-chloro-2,5-difluorobenzonitrile</strong> (7.83 g, 0.045 mol) in dry dimethylformamide (70 ml) under nitrogen atmosphere was treated with sodium hydride (60% dispersion in oil, 1.81 g, 0.045 mol). The mixture was stirred and heated to 60 C for 2 h, then quenched with water (500 ml). The products were extracted into diethyl ether (2 x 300 ml). The combined extracts were dried over magnesium sulphate, filtered and concentrated to give an oil. The crude material was purified on silica using 20% ether in isohexane to afford the title compound as a colourless oil (9.4 g, 80%). 1H NMR 300MHz (CDCl3) 7.43-7.3 (6H, m), 6.84 (1H, dd), 5.29 (1H, dd), 3.7-3.42 (2H, m), 2.4-2.04 (2H, m).

References: [1]Bioorganic and Medicinal Chemistry Letters,2011,vol. 21,p. 2468 - 2471.

16
[ 132794-08-2 ]
[ 135748-35-5 ]